Alteogen Eyes First-Mover Advantage For Eylea Biosimilar

Cites Benefit Of Formulation Patent As Aflibercept Rival Completes Phase I Trial

 
• By David Wallace
  
Chess White First Move
Alteogen Aims For A First-Mover Advantage On Biosimilar Eylea • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products